New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
07:12 EDTCGEN, BAYRYCompugen achieves initial milestone in collaboration with Bayer HealthCare
Compugen Ltd. (CGEN) disclosed hat it has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare (BAYRY). The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen. The milestone being announced today relates to the first preclinical milestone for one of two checkpoint protein candidates for which Compugen will receive a $1.2M payment out of the $30M potential milestone payments associated with joint preclinical research for the two programs. The collaboration and license agreement provides the framework for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen-discovered immune checkpoint regulators. Under the terms of the agreement, Bayer and Compugen are jointly pursuing a preclinical research program for each of the two candidates. Subsequently, Bayer will have full control over further development and have worldwide commercialization rights for potential cancer therapeutics. Under the terms of the agreement, Compugen has received an upfront payment of $10M and is eligible to receive over $500M in potential milestone payments for both checkpoint programs, plus an additional $30M of potential milestone payments associated with joint preclinical research for the two programs. Compugen is also eligible to receive royalties on global net sales from any resulting products under the collaboration.
News For CGEN;BAYRY From The Last 14 Days
Check below for free stories on CGEN;BAYRY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 8, 2014
07:15 EDTBAYRYIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
September 4, 2014
07:22 EDTBAYRYBayer unit aims to invest $1B before FY16 in U.S., Reuters says
Subscribe for More Information
05:37 EDTBAYRYRegeneron submits application for Eylea injection in Japan for macular edema
Subscribe for More Information
September 2, 2014
08:07 EDTBAYRYBoston Scientific closed agreement to acquire Interventional business of Bayer
Boston Scientific (BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer (BAYRY). The addition of the Bayer Interventional strong commercial organization and innovative technologies supports the Boston Scientific strategy to provide a comprehensive portfolio of solutions to treat peripheral vascular disease. The transaction includes the leading AngioJet Thrombectomy System and the Fetch 2 Aspiration Catheter, which are used in endovascular procedures to remove blood clots from blocked arteries and veins, and the JetStream Atherectomy System, used in an innovative and fast-growing therapy to remove plaque and thrombi from diseased arteries.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use